Dockets Management Staff, The National Community Pharmacists Association (NCPA) appreciates the opportunity to provide feedback on the Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use; Request for Comments. NCPA represents America's community pharmacists, including 19,400 independent community pharmacies. Almost half of all community pharmacies provide long-term care services and play a critical role in ensuring patients have immediate access to medications in both community and long-term care (LTC) settings. Together, our members represent a $78.5 billion healthcare marketplace, employ 240,000 individuals, and provide an expanding set of healthcare services to millions of patients every day. Our members are small business owners who are among America's most accessible healthcare providers. Please see attached for our full comments. NCPA thanks FDA for the opportunity to provide feedback, and we stand ready to work with FDA to offer possible solutions and ideas. Should you have any questions or concerns, please feel free to contact me at steve.postal@ncpa.org or (703) 600-1178.
FDANonrulemakingFDA-2022-N-2673
Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; Request for Comments
RIN
—
Last modified
Jan 20, 2023
Comment window
closed 1288d ago
National Community Pharmacists Association filings
1
Activity
National Community Pharmacists Association filed 1 comment on this docket between Jan 17, 2023 and Jan 17, 2023. 1 other organizations filed here. The comment window closed 1288d ago.
What National Community Pharmacists Association filed (1)
Jan 17, 2023· Comment from National Community Pharmacists Association· FDA-2022-N-2673-0169
Abstract
OPEN
View on regulations.gov →Co-filers (1)
See everyone who commented →- National Community Pharmacists AssociationTHIS ORG1 filing · confidence 97%
- National Association of Chain Drug Storestrade assoc.1 filing · confidence 97%